Design of Coibamide A Mimetics with Improved Cellular Bioactivity

Area of Science:

• Marine natural products chemistry
• Molecular pharmacology
• Drug discovery

Background:

• Coibamide A, a cyclic depsipeptide from marine cyanobacteria, exhibits potent cytotoxicity by inhibiting the Sec61 translocon.
• The Sec61 translocon is a crucial protein-channel involved in protein translocation across membranes.

Purpose of the Study:

• To design and synthesize novel coibamide A mimetics with improved stability and potency.
• To investigate the structure-activity relationships (SAR) of modified coibamide A analogs.
• To explore potential shared binding sites with other Sec61 inhibitors like apratoxin A.

Main Methods:

• Solid-phase synthesis of macrocyclic depsipeptide analogs.
• Structure-activity relationship (SAR) studies involving modifications of N-methylation and amino acid configurations.
• Cytotoxicity assays to evaluate the biological activity of synthesized compounds.

Main Results:

• A simplified macrocyclic scaffold with an alkyl linker showed reduced cytotoxicity compared to coibamide A.
• Introduction of a β-(4-biphenylyl)alanine (Bph) group and optimization of the Tyr(Me) position led to more potent coibamide A derivatives.
• Similar SAR trends between coibamide A and apratoxin A suggest a potentially shared binding site on the Sec61α translocon.

Conclusions:

• The study identified potent coibamide A derivatives with potential therapeutic applications.
• The findings highlight the importance of specific structural modifications for enhancing cytotoxic activity.
• Evidence suggests a common binding interaction of the Tyr(Me) side chain at the Sec61α luminal face for coibamide A and apratoxin A.